A randomized comparison of daunorubicin 90 mg/m(2) vs 60 mg/m(2) in AML induction: results from the UK NCRI AML17 trial in 1206 patients

Modifying induction therapy in acute myeloid leukemia (AML) may improve the remission rate and reduce the risk of relapse, thereby improving survival. Escalation of the daunorubicin dose to 90 mg/m(2) has shown benefit for some patient subgroups when compared with a dose of 45 mg/m(2), and has been...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Burnett, Alan K., Russell, Nigel H., Hills, Robert K., Kell, Jonathan, Cavenagh, Jamie, Kjeldsen, Lars, McMullin, Mary-Frances, Cahalin, Paul, Dennis, Mike, Friis, Lone, Thomas, Ian F., Milligan, Don, Clark, Richard E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4505010/
https://ncbi.nlm.nih.gov/pubmed/25833957
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-01-623447
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados